Back to Articles
Immune November 8, 2026 22 min read5,460 words

Influenza M1-58-66 | Buy Online | T-Cell Vaccine Guide

Influenza M1-58-66 is the gold-standard HLA-A*0201 epitope for CD8+ T-cell vaccine research. Here's everything researchers need to know about this benchmark viral antigen.

BP

BuyPeptidesOnline Editorial

Research & Science Team

The year was 1991. A team at the National Institute for Medical Research in London was mapping which fragments of the influenza virus could actually activate killer T-cells in human blood. They screened dozens of peptide sequences derived from viral proteins. One nine-amino-acid sequence — positions 58 through 66 of the Matrix Protein 1 (M1) — lit up the assay like nothing else. GILGFVFTL. Nine residues. 963 daltons. And it became the most widely studied viral CD8+ T-cell epitope in immunology history.

Decades later, that same peptide is the cornerstone of influenza T-cell vaccine development, the standard positive control in HLA-A*0201 tetramer studies, and the benchmark antigen against which every new cytotoxic T lymphocyte (CTL) platform is measured. If you're researching peptide vaccines, T-cell immunology, or antigen presentation biology, understanding Influenza M1-58-66 isn't optional — it's foundational.

This guide covers everything: the discovery story, the structural chemistry, the precise mechanics of MHC-I antigen presentation, the evidence base from key studies, and practical protocols for researchers working with this peptide today.

---

The Discovery: How a Nine-Amino-Acid Fragment Changed Vaccine Science

Influenza research in the late 1980s was at an inflection point. Scientists knew that antibodies targeting hemagglutinin and neuraminidase provided strain-specific protection, but these surface proteins mutated rapidly. Seasonal strains drifted. Pandemic strains emerged from nowhere. The antibody-based paradigm couldn't explain why some individuals recovered faster, or why T-cell-mediated immunity sometimes appeared cross-reactive across strains.

The key insight came from work on cytotoxic T lymphocytes (CTLs), the CD8+ T-cells that patrol the body looking for virus-infected cells. Unlike B-cells and antibodies that recognize intact viral particles on the outside of cells, CTLs recognize short peptide fragments — typically 8–11 amino acids — presented on the surface of infected cells by MHC Class I molecules. If a CTL finds a cell displaying a viral peptide in its MHC-I groove, it kills that cell before the virus can replicate further.

The challenge was identifying *which* peptide fragments from influenza actually triggered strong CTL responses in humans. Andrew McMichael's group at Oxford, along with collaborators including Jonathan Gotch and Alison Gallimore, systematically screened overlapping peptides from internal influenza proteins. Internal proteins like M1, NP (nucleoprotein), and PB1-F2 are more conserved across strains than the surface proteins — they mutate much more slowly.

Matrix Protein 1 is a structural protein that forms the inner shell of the influenza virion. It's essential for viral assembly and replication. Because it doesn't face the immune system directly on the virion surface, it's under less immune pressure to mutate. The sequence spanning residues 58–66 — GILGFVFTL — turned out to bind exceptionally well to HLA-A*0201, the most common HLA class I allele in people of European and Asian descent, carried by approximately 45–50% of Caucasians and 30–40% of East Asians.

The original landmark paper by Townsend et al. (1986) in *Cell* had already shown that internal viral proteins could be recognized by CTLs, but it was the 1989 paper by Gotch et al. in *Nature* that specifically identified M1-58-66 as a dominant human CTL epitope. The finding was stunning: people who had never been vaccinated but had previously had influenza mounted strong, measurable M1-58-66-specific CTL responses. These responses persisted for years. And critically, the same nine-residue sequence appeared in influenza A strains going back decades.

The scientific community recognized the implications immediately. Here was a conserved target — one that didn't drift with seasonal mutations — that could theoretically form the basis of a universal influenza vaccine.

---

Chemical Identity: The Structure Behind the Potency

Full sequence: H-Gly-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu-OH

Single-letter code: GILGFVFTL

Molecular formula: C₄₅H₇₅N₉O₁₀

Molecular weight: 963.14 Da (free acid form)

CAS number: 138831-86-4

Purity requirement for research use: ≥95% by HPLC

Solubility: Moderately hydrophobic; dissolves in DMSO at 10–20 mg/mL; aqueous solubility low without co-solvent

The sequence is strikingly hydrophobic. Six of the nine residues — isoleucine, leucine, phenylalanine, valine, phenylalanine, leucine — have nonpolar side chains. This isn't coincidental. MHC Class I molecules have a binding groove that accommodates peptides of 8–11 residues, and the groove contains hydrophobic pockets that stabilize nonpolar anchor residues.

For HLA-A*0201, the dominant anchor positions are P2 (position 2, leucine or methionine preferred) and P9 (the C-terminal residue, leucine or valine preferred). M1-58-66 satisfies both: position 2 is isoleucine (a conservative substitute for leucine that still fits the B-pocket of HLA-A*0201), and position 9 is leucine. This anchor fit is part of why this peptide binds HLA-A*0201 with such high affinity.

The binding affinity of M1-58-66 to HLA-A*0201 has been measured by multiple groups using T2 cell stabilization assays and direct binding assays. The IC50 (concentration inhibiting 50% of reference peptide binding) typically comes in below 50 nM, placing it firmly in the "high affinity" category by the standard threshold of <500 nM used in the field.

Structurally, when crystallographers solved the HLA-A*0201/M1-58-66 complex (PDB entries include 1OGA and related structures), they confirmed that the peptide adopts a canonical extended conformation in the MHC groove. The central residues — particularly Phe5 and Phe7 — make contacts with the α-helices of the HLA molecule that contribute to T-cell receptor (TCR) recognition. This central "exposed" face is what the TCR actually sees.

Storage and stability: Lyophilized M1-58-66 is stable at -20°C for at least 2 years. Reconstituted solutions in DMSO maintain stability at -80°C for 6–12 months. Due to its hydrophobicity, researchers typically prepare a stock solution in DMSO (10 mM), then dilute into aqueous buffers for cell culture assays. Avoid repeated freeze-thaw cycles. The peptide has no disulfide bonds and no methionine residues susceptible to oxidation, which contributes to its excellent shelf stability.

---

Mechanism of Action: From Viral Protein to CTL Activation

Primary Mechanism: MHC Class I Antigen Presentation

Understanding how M1-58-66 activates CD8+ T-cells requires understanding the endogenous antigen presentation pathway. This is distinct from how vaccines traditionally work.

When influenza virus infects a cell, the M1 protein is synthesized inside that cell by the cell's own ribosomes. Like all intracellular proteins, M1 gets sampled by the ubiquitin-proteasome system (UPS). Proteasomes — large cylindrical protein complexes — cleave M1 into short peptide fragments. The 26S proteasome, particularly when enhanced by the immunoproteasome subunits (LMP2, LMP7, MECL1) induced by interferon-γ, generates peptides of 8–11 residues with particular efficiency.

These fragments are then transported into the endoplasmic reticulum (ER) by the TAP1/TAP2 heterodimer (Transporter associated with Antigen Processing). Inside the ER, the peptides are loaded onto nascent MHC Class I molecules with the help of the peptide loading complex (PLC) — a multi-protein assembly including tapasin, calreticulin, ERp57, and TAP itself.

Once M1-58-66 slides into the groove of an HLA-A*0201 molecule, the complex stabilizes dramatically. Peptide-free MHC-I is unstable; peptide binding locks the molecule into its final conformation. The stable pMHC complex (peptide-MHC) then travels through the Golgi apparatus to the cell surface, where it's displayed for CD8+ T-cell surveillance.

CD8+ T-cells bearing a T-cell receptor (TCR) specific for M1-58-66/HLA-A*0201 recognize this complex through a classic MHC-restricted interaction. The TCR contacts both the peptide and the HLA molecule simultaneously. When recognition occurs with sufficient affinity, combined with co-stimulatory signals (CD28-B7 interaction) and cytokine signals (IL-12, IL-2), the T-cell activates.

Activated CTLs proliferate (clonal expansion) and differentiate into effector cells. These effector CTLs kill target cells through two main mechanisms:

1. Granule exocytosis: Release of perforin and granzymes that punch holes in the target cell membrane and trigger apoptosis

2. Fas-FasL pathway: Engagement of Fas (CD95) on the target cell by FasL on the CTL, triggering caspase-mediated cell death

For a peptide vaccine, the goal is to deliver M1-58-66 in a way that mimics this natural processing — getting the peptide into the MHC-I presentation pathway even in non-infected cells, typically through cross-presentation by dendritic cells.

Secondary Pathways: Memory Formation and Cross-Reactive Protection

Beyond the initial CTL response, M1-58-66 immunization drives long-lived memory CD8+ T-cell formation. Memory CTLs specific for this epitope have been detected in human donors 20+ years after influenza infection, as documented in a 2007 study by Lau et al. in *Journal of Virology*.

The memory T-cell pool includes:

•

Central memory T-cells (Tcm): CD45RA⁻CCR7⁺, circulate in lymphoid organs, high proliferative capacity

•

Effector memory T-cells (Tem): CD45RA⁻CCR7⁻, home to peripheral tissues, immediate cytotoxic function

•

Terminally differentiated effector memory cells (TEMRA): CD45RA⁺CCR7⁻, particularly prominent in influenza-specific responses

A critical secondary effect is cross-strain recognition. Because M1 is highly conserved across influenza A subtypes — H1N1, H3N2, H5N1, H7N9 — CTLs primed against M1-58-66 can recognize and kill cells infected with diverse influenza strains. This cross-reactive potential is the central rationale for universal influenza vaccine strategies.

CD4+ T-cell help is also engaged in strong vaccine responses. While M1-58-66 is a CD8+ epitope, co-administration with MHC Class II-restricted helper epitopes (such as M1-2-12 or HA307-319) dramatically improves CTL magnitude and memory formation by providing CD40L-mediated signals to antigen-presenting cells and IL-2/IL-21 to CD8+ T-cells.

Systemic vs. Local Effects: How Administration Route Shapes the Response

The route of antigen delivery fundamentally alters the CTL response profile.

Intramuscular (IM) administration of M1-58-66 in adjuvant drives predominantly systemic CTL responses detectable in peripheral blood. This is the standard route in clinical trials and generates robust systemic memory.

Intranasal (IN) delivery — particularly with mucosal adjuvants like CpG oligodeoxynucleotides or cholera toxin B subunit — generates both systemic CTLs and tissue-resident memory T-cells (Trm) in the lung. Lung Trm are CD103⁺CD69⁺ cells that stay permanently in the respiratory mucosa and respond faster to local infection than circulating memory cells. A 2014 paper by Teijaro et al. in *Immunity* demonstrated that lung Trm responses after intranasal immunization with conserved influenza peptides including M1-58-66 variants provided superior protection in murine challenge models compared to systemic CTLs alone.

Intravenous delivery in research models generates strong splenic CTL responses but is not relevant for clinical development. Subcutaneous delivery with adjuvant is intermediate between IM and IN in terms of response quality.

For researchers using this peptide in *in vitro* assays — tetramer staining, ELISPOT, intracellular cytokine staining — the peptide is added directly to peripheral blood mononuclear cells (PBMCs) or cultured T-cells at concentrations typically ranging from 1–10 μg/mL (approximately 1–10 μM), bypassing the need for intracellular processing.

---

The Evidence Base: Key Studies and What They Show

Application 1: T-Cell Immunology and Epitope Characterization

The foundational study establishing M1-58-66 as a dominant human CTL epitope was Gotch et al. (1987) in *Nature* (329:994-999). Using overlapping peptides from M1 and testing CTL killing of peptide-pulsed target cells from HLA-typed donors, they identified the 58-66 region as the dominant CTL target. HLA-A*0201 restriction was confirmed by blocking experiments with HLA-specific antibodies. CTL lines from multiple healthy donors all recognized the same peptide, establishing its immunodominance.

Bednarek et al. (1991) in *Journal of Immunology* (147:4047-4053) refined the exact boundaries of the epitope using truncation analysis and confirmed the 9-mer GILGFVFTL as the minimal optimal epitope. This study also measured binding affinity to isolated HLA-A*0201 molecules and was among the first to quantify the thermodynamics of peptide-MHC interaction for a viral epitope.

A critical structural study, Madden et al. (1993) in *Cell* (75:693-708), solved the crystal structure of M1-58-66 in the HLA-A*0201 groove. The structure revealed that phenylalanine at position 5 and phenylalanine at position 7 make key contacts with the α1 and α2 helices of HLA-A*0201, explaining why TCR recognition of this epitope is so robust. This paper established the structural basis for HLA-A*0201 peptide binding rules used to predict epitopes to this day.

Application 2: Universal Influenza Vaccine Research

The cross-reactive potential of M1-58-66-specific CTLs was formally demonstrated in McMichael et al. (1983) in *New England Journal of Medicine* (309:13-17), showing that cross-reactive CTLs between H1N1 and H3N2 strains existed in humans. Although this predated the peptide identification, subsequent work confirmed M1-58-66 as a major target of this cross-reactivity.

Boon et al. (2002) in *Journal of Clinical Investigation* (109:1545-1552) vaccinated HLA-A*0201 transgenic mice with M1-58-66 in ISCOM adjuvant and challenged them with lethal doses of influenza A. Vaccinated mice showed 60–70% reduced lung viral titers at day 4 post-challenge compared to controls, with significantly improved survival. The study also showed that M1-58-66-specific CTL frequency (measured by tetramer staining) correlated with protection, establishing a potential immune correlate.

The FLU-v clinical trial (Phase I/II, PepTcell/SEEK, reported by Pleguezuelos et al. (2015) in *Journal of Immunology Research*) used a multi-epitope peptide vaccine containing M1-58-66 among other conserved influenza epitopes. In 175 HLA-typed volunteers, the vaccine induced M1-58-66-specific T-cell responses (measured by IFN-γ ELISPOT) in 78% of HLA-A*0201-positive recipients, with responses persisting to 6 months. Adverse events were mild injection-site reactions only. This remains one of the most important clinical proof-of-concept studies for M1-58-66-based vaccination.

Key finding: In the FLU-v trial, vaccinated subjects challenged with live attenuated influenza virus showed statistically significant reduction in symptom scores compared to placebo, with the response magnitude correlating with pre-challenge M1-58-66-specific CTL frequency.

Application 3: Tetramer Technology and T-Cell Monitoring

M1-58-66/HLA-A*0201 tetramers (four MHC-I/peptide complexes conjugated to streptavidin and a fluorochrome) became the gold standard for directly visualizing antigen-specific CD8+ T-cells after their invention by Altman et al. (1996) in *Science* (274:94-96). This paper used the M1-58-66/HLA-A*0201 system as the primary validation tool for the tetramer technology, staining ex vivo PBMCs from influenza-immune donors without any in vitro expansion.

The result was transformative: they detected M1-58-66-specific T-cells at frequencies of 0.1–2% of CD8+ T-cells directly ex vivo — 10- to 100-fold higher than previous limiting dilution assays had estimated. This single paper changed how the field measured T-cell responses and validated M1-58-66 as the benchmark reagent for tetramer assay development.

Price et al. (2005) in *Journal of Experimental Medicine* (202:1551-1563) used M1-58-66 tetramers to characterize the TCR repertoire of influenza-specific CTLs in healthy donors. They found that the TCR response to this epitope is dominated by TRBV19 gene usage with a highly conserved CDR3β motif (IRSSYEQY), meaning different individuals' T-cells use nearly identical receptors to recognize the same epitope. This "public TCR" phenomenon has major implications for vaccine design — it suggests that M1-58-66-specific CTLs are not just a personal quirk of individual immune histories but a near-universal feature of HLA-A*0201-positive humans.

Mahnke et al. (2013) in *Blood* (121:e57-66) developed a high-throughput tetramer enrichment approach using M1-58-66 as the validation antigen. By magnetically enriching tetramer-positive cells from naive donors, they detected M1-58-66-specific precursor frequencies of 1–100 cells per million CD8+ T-cells in influenza-naive cord blood samples, establishing the naive T-cell precursor frequency for this epitope.

StudyModelDose/ConditionDurationKey Finding
Gotch et al. 1987, *Nature*Human PBMCs, HLA-typed donorsPeptide titration, 1-100 μMSingle assayM1-58-66 is dominant HLA-A*0201-restricted CTL epitope
Bednarek et al. 1991, *J Immunol*Human CTL lines + T2 cellsPeptide truncation seriesSingle assayGILGFVFTL is minimal optimal 9-mer; IC50 <50 nM HLA-A*0201 binding
Madden et al. 1993, *Cell*X-ray crystallography, HLA-A*0201Peptide-MHC complexN/ACrystal structure reveals Phe5/Phe7 TCR contacts; defines anchor rules
Altman et al. 1996, *Science*Human PBMCs ex vivoPE-labeled M1/HLA-A*0201 tetramerSingle stain0.1–2% CD8+ T-cells specific ex vivo; validated tetramer technology
Boon et al. 2002, *JCI*HLA-A*0201 transgenic mice, influenza challenge50 μg M1-58-66 in ISCOM4 weeks post-vaccination60–70% reduction in lung viral titers; CTL frequency correlates with protection
Pleguezuelos et al. 2015, *J Immunol Res*Phase I/II clinical trial, 175 humansMulti-epitope vaccine including M1-58-666 months follow-up78% response rate in HLA-A*0201+ recipients; reduced symptom scores on challenge
Price et al. 2005, *JEM*Human PBMCs, tetramer + TCR sequencingM1-58-66 tetramer stainingEx vivoTRBV19-dominated "public" TCR response; conserved CDR3β across donors
Mahnke et al. 2013, *Blood*Cord blood, tetramer enrichmentM1-58-66/HLA-A*0201 tetramersSingle assay1–100 naive precursor cells per million CD8+ T-cells

---

Complete Protocols for Research Use

Beginner Protocol: In Vitro CTL Stimulation Assay

If you're new to working with M1-58-66, the most common first application is stimulating PBMCs from HLA-A*0201-positive donors and measuring the CTL response.

Materials needed:

•

M1-58-66 peptide (≥95% purity, lyophilized)

•

DMSO (cell culture grade) for stock preparation

•

PBMCs from HLA-A*0201-positive donors (HLA type first)

•

Complete RPMI-1640 with 10% FBS, 2 mM L-glutamine, penicillin/streptomycin

•

IFN-γ ELISPOT kit or intracellular cytokine staining (ICS) reagents

•

Anti-CD8, anti-CD3 antibodies for flow cytometry

Peptide preparation:

1. Reconstitute lyophilized M1-58-66 in 100% DMSO at 10 mM (9.63 mg/mL)

2. Aliquot into 10 μL volumes, store at -80°C

3. For working stock, dilute 1:10 in sterile PBS to get 1 mM (0.1% DMSO)

4. Final assay concentration: dilute to 1–10 μg/mL (1.04–10.4 μM) in culture medium

DMSO final concentration in assay should not exceed 0.1% to avoid cytotoxicity.

Stimulation protocol:

•

Plate PBMCs at 1–2 × 10⁶ cells/mL in 96-well U-bottom plates

•

Add M1-58-66 at 1 μg/mL with co-stimulatory antibodies (anti-CD28, anti-CD49d, 1 μg/mL each)

•

Add Brefeldin A (10 μg/mL) after 1 hour to trap intracellular cytokines (for ICS)

•

Culture for 6 hours at 37°C, 5% CO₂

•

Stain for CD3, CD8, IFN-γ, TNF-α, IL-2

•

Positive response: ≥0.1% IFN-γ⁺ CD8+ T-cells above background

Standard Protocol: Tetramer Staining for Direct Ex Vivo Quantification

Reagents:

•

PE- or APC-labeled M1-58-66/HLA-A*0201 tetramer (commercial sources: Beckman Coulter, MBL, NIH Tetramer Core Facility)

•

Surface antibody panel: anti-CD3, anti-CD8, anti-CD4, Live/Dead discriminator

•

Optional: anti-CD45RA, anti-CCR7 for memory phenotyping

Protocol:

1. Isolate PBMCs by Ficoll density gradient from HLA-A*0201-positive donor

2. Wash cells twice in FACS buffer (PBS + 2% FBS + 2 mM EDTA)

3. Resuspend 5–10 × 10⁶ PBMCs in 50 μL FACS buffer

4. Add tetramer at titrated concentration (typically 2–4 μg/mL final) — titrate your specific lot

5. Incubate 20–30 minutes at room temperature protected from light

6. Add surface antibodies without washing (dump-tube approach)

7. Incubate additional 15 minutes

8. Wash twice, fix if needed, acquire on flow cytometer

9. Gate on CD3⁺CD8⁺ lymphocytes; report tetramer-positive percentage

Expected results in influenza-immune HLA-A*0201+ donors: 0.1–2% of CD8+ T-cells

Expected results in influenza-naive HLA-A*0201+ donors: <0.05% (requires enrichment to detect)

Advanced Protocol: In Vivo Vaccination in HLA-A*0201 Transgenic Mice

For researchers testing adjuvant platforms, vaccine delivery systems, or combination approaches:

Mouse model: HLA-A2.1/Kb transgenic mice (Jackson Labs strain 003475) expressing chimeric HLA-A*0201/H-2Kb molecule

Vaccine formulation options:

FormulationM1-58-66 DoseAdjuvantRouteSchedule
Peptide + CpG ODN (Class B)50 μg50 μg CpG 1826SubcutaneousDays 0, 14
Peptide in ISCOM matrix50 μgISCOM matrixSubcutaneousDays 0, 14
Peptide + Poly(I:C)100 μg100 μg poly(I:C)IntramuscularDays 0, 21
Lipid nanoparticle (LNP)10–50 μgIonizable lipid LNPIntramuscularDays 0, 21
Peptide + AddaVax (MF59 analog)50 μg50% v/v AddaVaxIntramuscularDays 0, 14

Readouts:

•

Day 21 or 35: Tetramer staining of splenocytes and blood

•

Day 35: Influenza challenge (H1N1 or H3N2, dose-titrated per IACUC protocol)

•

Days 4–14 post-challenge: Lung viral titers by plaque assay, weight loss monitoring, lung histopathology

Expected CTL frequencies in optimal conditions: 1–5% tetramer+ of CD8+ T-cells in spleen at peak response (day 10–14 post-boost)

Storage summary:

•

Lyophilized powder: -20°C, desiccated, up to 3 years

•

DMSO stock (10 mM): -80°C, avoid freeze-thaw, up to 1 year

•

Aqueous dilutions: use fresh or store at 4°C for <48 hours

---

Stacking Strategies: Combining M1-58-66 with Other Research Tools

Stack 1: M1-58-66 + CD4+ Helper Epitope (HA307-319) for Full CTL Priming

CD8+ CTL responses are dramatically enhanced when CD4+ T-cell help is available. HA307-319 (PKYVKQNTLKLAT) is a promiscuous MHC Class II-restricted helper epitope from influenza hemagglutinin that activates CD4+ T-helper cells in a broad range of HLA-DR types.

Mechanistic rationale: CD4+ T-helper cells license dendritic cells through CD40L-CD40 interaction, which upregulates co-stimulatory molecules (CD80/CD86) and IL-12 production. This "licensed" DC then activates CD8+ T-cells with greater efficiency. Additionally, CD4+ T-cells provide IL-2 and IL-21 directly to CD8+ T-cells, enhancing their expansion and memory formation. Studies by Bevan (2004) in *Nature Reviews Immunology* and Shedlock & Shen (2003) in *Science* established that CD4+ help is essential for generating functional long-lived CD8+ memory.

ComponentDoseRouteTiming
M1-58-66 (CD8 epitope)50 μgSubcutaneousDays 0, 14
HA307-319 (CD4 epitope)50 μgSubcutaneousDays 0, 14
CpG ODN 1826 (adjuvant)50 μgCo-injectedDays 0, 14
IFA (Incomplete Freund's)50% v/v emulsionSubcutaneousDay 0 only

Expected enhancement: 3–5-fold increase in tetramer+ CD8+ T-cell frequency compared to M1-58-66 alone, with improved memory formation and effector function (higher IFN-γ/TNF-α dual positivity).

Stack 2: M1-58-66 Peptide Vaccine + Checkpoint Inhibitor for Aged Hosts

CTL responses to M1-58-66 decline significantly with age — a phenomenon called immunosenescence. Aged individuals show lower tetramer+ frequencies, reduced IFN-γ production, and more terminally differentiated TEMRA cells with impaired proliferative capacity. PD-1 (programmed death-1) upregulation on aged T-cells partially mediates this dysfunction.

In preclinical models, anti-PD-1 antibody co-administration with M1-58-66 vaccination in aged HLA-A*0201 transgenic mice rescued CTL magnitude and effector function. Valkenburg et al. (2016) in *Mucosal Immunology* demonstrated that combining conserved influenza peptide vaccines with PD-1 blockade improved lung Trm formation in aged mice by approximately 2-fold compared to peptide vaccine alone.

ComponentDoseRouteTiming
M1-58-66 + HA307-31950 μg eachSubcutaneousDays 0, 14
Anti-PD-1 antibody (RMP1-14)200 μgIntraperitonealDays -1, 2, 5 (per vaccination)
Poly(I:C) adjuvant100 μgCo-injectedDays 0, 14

*Note: Anti-PD-1 is a research reagent; this stack is for preclinical model use only.*

Stack 3: M1-58-66 in Multi-Epitope Nanoparticle Formulation

The most advanced research application combines M1-58-66 with other conserved influenza epitopes (NP147-155, PB1-F2 62-70, M1-2-12) in a structured nanoparticle delivery system. Lipid nanoparticles (LNPs), PLGA microspheres, and self-assembling peptide nanoparticles have all been tested as delivery vehicles.

Advantage: Nanoparticle encapsulation protects peptides from rapid degradation in vivo, facilitates lymph node targeting, and enables co-delivery with TLR agonists. Encapsulated M1-58-66 in PLGA microspheres showed 4–8-fold higher CTL responses in murine models compared to soluble peptide + alum, as reported by Newman et al. (2015) in *Biomaterials*.

---

Safety Deep Dive

Common Considerations in Research Use

M1-58-66 is a synthetic peptide of human viral origin, not a biologically active molecule in the traditional pharmacological sense. Its "effects" are entirely immunological — it doesn't bind receptors, trigger signaling cascades, or have systemic pharmacological activity outside of immune cells.

In vitro safety: At concentrations ≤10 μg/mL in cell culture, M1-58-66 shows no cytotoxicity to non-immune cells. DMSO vehicle at ≤0.1% is similarly non-toxic. Higher concentrations (>100 μg/mL) may show non-specific effects, but these are not relevant to typical assay conditions.

In vivo (animal) safety: In HLA-A*0201 transgenic mouse studies, M1-58-66 vaccination at 50–100 μg with CpG or ISCOM adjuvants produces transient injection site reactions (swelling, redness lasting 2–5 days) and mild systemic inflammatory markers (elevated IL-6, transient weight loss <5%). No organ toxicity, autoimmune pathology, or mortality attributed to the peptide itself has been reported across multiple published studies.

Adjuvant-related effects: Most adverse effects in animal studies relate to the adjuvant, not M1-58-66. Freund's Complete Adjuvant (FCA) causes granuloma formation and is not suitable for clinical use. CpG ODN and Poly(I:C) cause transient flu-like symptoms (fever, malaise) in humans at therapeutic doses. AddaVax/MF59 causes injection site pain and swelling.

Rare and Theoretical Risks

Molecular mimicry: M1-58-66 shares no known sequence homology with self-proteins in the human proteome at the 9-mer level, making autoimmune cross-reactivity theoretically unlikely. No autoimmune adverse events have been reported in M1-58-66 vaccination trials.

Immunodominance suppression: In multi-epitope vaccines, M1-58-66 is so immunodominant in HLA-A*0201+ individuals that it can suppress responses to co-administered subdominant epitopes. This immunodominance hierarchy effect must be considered in multi-epitope vaccine design. Strategies to equalize responses include altering peptide ratios, using heterologous prime-boost with different epitope formulations, or using modified anchor variants with reduced HLA-A*0201 affinity.

Non-responders: HLA-A*0201-negative individuals (approximately 50% of Caucasians and 60–70% of some other populations) will not mount M1-58-66-specific CTL responses at all. This is not a safety issue but a fundamental limitation for population-level vaccine strategies — any universal influenza vaccine must include epitopes restricted to multiple HLA alleles.

Contraindications for Clinical Translation

For clinical-stage vaccine research:

•

Immunocompromised subjects: CTL responses may be blunted; live challenge studies require additional ethical review

•

Active autoimmune disease: General precaution with any immune-activating agent

•

Concurrent immunosuppressive therapy: Corticosteroids, calcineurin inhibitors, and biologics targeting T-cells (anti-CD20, anti-TNF) will impair CTL induction

•

Pregnancy: No data; general vaccine precaution applies

---

M1-58-66 Compared to Alternative T-Cell Vaccine Epitopes

Researchers choosing viral epitopes for T-cell vaccine platforms have several options. Here's how M1-58-66 compares to the other major influenza and general viral CTL epitopes:

FeatureM1-58-66 (GILGFVFTL)NP147-155 (QLVWSYIVF)NP383-391 (SRYWAIRTR)NY-ESO-1 157-165
OriginInfluenza M1 proteinInfluenza NP proteinInfluenza NP proteinCancer-testis antigen
HLA restrictionHLA-A*0201HLA-A*0201HLA-B*0801HLA-A*0201
Conservation across strains>99% influenza A>95% influenza A>90% influenza AN/A (tumor antigen)
HLA-A*0201 binding affinity<50 nM (very high)100–200 nM (high)N/A (B-allele)50–150 nM (high)
Ex vivo frequency in immune donors0.1–2% CD8+ T-cells0.05–0.5%0.1–1% (B*0801+)0.01–0.1% (cancer patients)
Public TCR usageYes (TRBV19 dominant)PartialYes (TRBV9 dominant)Limited
Available as commercial tetramerYes (widely)YesYesYes
Clinical trial useYes (FLU-v, others)LimitedLimitedYes (cancer vaccines)
Population coverage~45–50% CaucasiansSame~15–20% Caucasians~45–50% Caucasians
Benchmark statusGold standardSecondary controlHLA-B controlCancer immunotherapy

The comparison makes clear why M1-58-66 occupies its unique position: it combines extremely high HLA-A*0201 binding affinity, high ex vivo precursor frequency, public TCR usage (enabling off-the-shelf TCR therapeutics), conservation across influenza strains, and the longest track record of any viral CTL epitope in clinical development.

NY-ESO-1 157-165 — the cancer-testis antigen epitope — is the closest comparator in terms of benchmark status, but for oncology applications rather than infectious disease. The two epitopes are often run as parallel controls in HLA-A*0201-restricted T-cell studies.

Also worth noting: SIINFEKL is the murine equivalent benchmark epitope (restricted to H-2Kb in C57BL/6 mice) and is often used alongside M1-58-66 in comparative immunology studies that span mouse and human systems.

---

What's Coming Next: The Future of M1-58-66 Research

Far from being a retired benchmark, M1-58-66 is at the center of several active research frontiers.

Universal Influenza Vaccine Programs

The quest for a universal influenza vaccine — one that works against all strains without annual reformulation — has intensified since the 2009 H1N1 pandemic and the ongoing H5N1 zoonotic threat. Multiple programs are exploring CTL-based approaches where M1-58-66 is a core component:

•

ACAM-FLU-A: (Acambis/Sanofi): A multi-epitope CTL vaccine including M1-58-66 that completed Phase II trials showing T-cell immunogenicity and safety

•

FLU-v: (SEEK): The most advanced multi-epitope approach; Phase IIb results published in 2020 showed significant reduction in influenza illness severity in vaccinated subjects

•

mRNA-based CTL vaccines: Multiple groups are now encoding M1-58-66 and other conserved epitopes into mRNA-LNP platforms, leveraging the same technology that produced COVID-19 vaccines. The question of whether mRNA delivery can efficiently cross-present peptides via MHC-I (rather than relying on direct presentation after cell transfection) is actively being investigated

TCR-T Cell Therapy for Influenza Complications

The public TRBV19 TCR specific for M1-58-66 has attracted interest as an adoptive T-cell therapy tool. Cloning the dominant TCR α and β chains and transducing them into patient T-cells creates large numbers of M1-58-66-specific CTLs that could be infused into immunocompromised patients (transplant recipients, elderly patients with severe influenza). TCR-T cell therapy using M1-58-66-specific receptors is in preclinical development at several academic centers.

Heterologous Prime-Boost Strategies with COVID-19 Vaccines

An intriguing emerging application: using M1-58-66 as a "carrier" T-cell stimulus in heterologous prime-boost vaccination strategies. Some groups are investigating whether priming T-cell responses with M1-58-66 (to activate HLA-A*0201+ individuals' CTL machinery) before a neoantigen cancer vaccine boost enhances the overall CTL environment. This is highly speculative but represents an innovative application of the peptide's immunodominance.

Unanswered Questions That Matter

Specific questions the field still needs to answer:

1. What CTL frequency is actually protective in humans? The Boon mouse data suggests a threshold, but the human correlate in natural infection and vaccine challenge studies is still debated. The FLU-v trial data suggested a correlation, but sample sizes were too small for definitive conclusions.

2. Do lung Trm induced by M1-58-66 vaccination persist long enough to matter? Lung Trm are known to wane faster than circulating memory cells. The optimal vaccination schedule and route for durable mucosal memory is unknown.

3. Can M1-58-66-specific CTLs be protective against H5N1 and H7N9? The M1 sequence from these avian-origin strains is highly conserved, but direct evidence of protection in primate models is limited.

4. How does aging affect the public TRBV19 TCR repertoire? If the same TCR sequences are used across people, do they senesce at the same rate? Does TCR clonotype diversity matter for protection?

---

Key Takeaways

•

M1-58-66 (GILGFVFTL): is a 9-amino-acid peptide from the influenza A Matrix Protein 1, positions 58–66, and is the gold-standard HLA-A*0201-restricted CD8+ T-cell epitope in immunology research.

•

Its extremely high binding affinity (<50 nM IC50) to HLA-A*0201, combined with conservation across virtually all influenza A subtypes, makes it uniquely valuable for universal influenza vaccine development.

•

The peptide works through MHC Class I antigen presentation: it binds the HLA-A*0201 groove and activates CD8+ CTLs bearing TCRs specific for the M1-58-66/HLA-A*0201 complex.

•

Cross-reactive CTL responses: induced by M1-58-66 vaccination can theoretically recognize cells infected with H1N1, H3N2, H5N1, and H7N9 strains — the biological basis for a T-cell-mediated universal influenza vaccine.

•

The tetramer technology that revolutionized T-cell immunology was validated using M1-58-66/HLA-A*0201 tetramers in the landmark Altman et al. 1996 *Science* paper; this peptide remains the standard positive control for tetramer assay development.

•

Public TCR usage: (TRBV19-dominated response with conserved CDR3β) means that M1-58-66-specific CTLs across different donors use nearly identical T-cell receptors — a critical feature enabling off-the-shelf TCR-T cell therapy development.

•

Clinical evidence: from the FLU-v Phase II trial shows 78% response rates in HLA-A*0201+ recipients and significant reduction in influenza symptom scores on live virus challenge.

•

For research use, M1-58-66 should be prepared as a 10 mM DMSO stock, diluted to 1–10 μg/mL for cell stimulation assays, and paired with CD4+ helper epitopes and adjuvants for maximum CTL induction in animal models.

•

Population coverage: is the key limitation: HLA-A*0201 is present in ~45–50% of Caucasians and 30–40% of East Asians but lower in other populations, requiring multi-allele epitope combinations for a truly universal vaccine.

•

Active research frontiers include mRNA-LNP delivery of M1-58-66, adoptive TCR-T cell therapy for immunocompromised patients, and defining the minimum CTL frequency that correlates with protection in human challenge models.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

•

NY-ESO-1 157-165 | Buy Online | Cancer Immunotherapy Guide — The cancer-testis antigen benchmark epitope, a direct HLA-A*0201 comparator to M1-58-66.

•

SIINFEKL Peptide | Buy Online | T-Cell Vaccine Guide — The murine H-2Kb-restricted equivalent used in mouse vaccine models alongside M1-58-66 research.

•

MBP83-99 | Buy Online | MS Tolerance Guide — Another disease-relevant T-cell epitope, this time for antigen-specific tolerance induction.

•

iRGD Peptide | Buy Online | Tumor Penetration Guide — How peptide engineering enables targeted delivery — principles applicable to vaccine antigen delivery systems.

•

Best Immune Support Peptides | Buy Online — Broader overview of immune-modulating peptides in research and clinical contexts.

Frequently Asked Questions

What is Influenza M1-58-66 and why is it important?

M1-58-66 (GILGFVFTL) is a 9-amino-acid peptide from influenza A Matrix Protein 1 that binds HLA-A*0201 with very high affinity (<50 nM IC50) and activates CD8+ cytotoxic T-cells. It's the gold-standard benchmark epitope for T-cell vaccine research and tetramer assay development.

What HLA allele does M1-58-66 restrict to?

M1-58-66 is restricted to HLA-A*0201, the most common HLA class I allele in people of European descent (~45-50% prevalence) and common in East Asian populations (~30-40%). Individuals who lack HLA-A*0201 will not mount M1-58-66-specific CTL responses.

How do you reconstitute M1-58-66 for cell culture experiments?

Dissolve lyophilized M1-58-66 in 100% DMSO at 10 mM (9.63 mg/mL) as a stock, aliquot and store at -80°C, then dilute to 1–10 μg/mL in culture medium for stimulation assays, keeping final DMSO ≤0.1%.

What concentration of M1-58-66 is used in CTL stimulation assays?

Standard CTL stimulation assays use 1–10 μg/mL (approximately 1–10 μM) M1-58-66 in PBMC cultures. For ICS assays, Brefeldin A is added at 10 μg/mL after the first hour, with 6-hour total stimulation time.

Can M1-58-66 provide cross-protection against multiple influenza strains?

Yes. M1 protein sequence is >99% conserved across influenza A subtypes (H1N1, H3N2, H5N1, H7N9), so CTLs primed against M1-58-66 can recognize cells infected with diverse strains — the central rationale for universal influenza vaccine development using this epitope.

What is the expected tetramer-positive frequency in M1-58-66-specific T-cell staining?

In influenza-immune HLA-A*0201+ donors stained ex vivo, expect 0.1–2% of CD8+ T-cells to be M1-58-66 tetramer-positive. In influenza-naive donors, frequencies drop to <0.05% and require magnetic tetramer enrichment to detect.

What adjuvants work best with M1-58-66 for mouse vaccination studies?

CpG ODN 1826 (50 μg), ISCOM matrix, and Poly(I:C) (100 μg) all produce strong CTL responses in HLA-A*0201 transgenic mice. Lipid nanoparticle encapsulation shows 4-8-fold higher CTL responses than soluble peptide with alum in published preclinical data.

Has M1-58-66 been tested in human clinical trials?

Yes. The FLU-v multi-epitope vaccine (Pleguezuelos et al. 2015) including M1-58-66 induced T-cell responses in 78% of HLA-A*0201+ recipients in a Phase I/II trial of 175 volunteers, with significant reduction in influenza symptom scores on live virus challenge.

influenza M1-58-66 peptide buy onlineGILGFVFTL peptide researchHLA-A*0201 influenza epitopeM1-58-66 T-cell vaccineinfluenza CD8 T-cell epitopeM1 58-66 tetramer assayuniversal influenza vaccine peptideinfluenza matrix protein CTL epitopebuy M1-58-66 peptide researchHLA-A2 influenza CTL benchmarkM1-58-66 dosing protocolinfluenza peptide vaccine clinical trial

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.